Liquidia (NASDAQ:LQDA) vs. Harrow (NASDAQ:HROW) Financial Analysis

Harrow (NASDAQ:HROW – Get Free Report) and Liquidia (NASDAQ:LQDA – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, risk, profitability, earnings and institutional ownership.

Risk and Volatility

Harrow has a beta of 0.18, meaning that its stock price is 82% less volatile than the S&P 500. Comparatively, Liquidia has a beta of 0.4, meaning that its stock price is 60% less volatile than the S&P 500.

Earnings and Valuation

This table compares Harrow and Liquidia”s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Harrow $303.25 million 3.62 -$5.14 million ($0.78) -37.51
Liquidia $158.32 million 32.22 -$68.92 million ($1.23) -46.02

Harrow has higher revenue and earnings than Liquidia. Liquidia is trading at a lower price-to-earnings ratio than Harrow, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Harrow and Liquidia’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Harrow -9.39% -69.81% -5.16%
Liquidia -15.15% 264.65% 44.19%

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Harrow and Liquidia, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Harrow 2 1 6 0 2.44
Liquidia 1 5 5 1 2.50

Harrow presently has a consensus target price of $66.20, suggesting a potential upside of 126.29%. Liquidia has a consensus target price of $75.23, suggesting a potential upside of 32.90%. Given Harrow’s higher probable upside, equities research analysts clearly believe Harrow is more favorable than Liquidia.

Insider & Institutional Ownership

72.8% of Harrow shares are owned by institutional investors. Comparatively, 64.5% of Liquidia shares are owned by institutional investors. 12.8% of Harrow shares are owned by company insiders. Comparatively, 25.6% of Liquidia shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Harrow beats Liquidia on 8 of the 15 factors compared between the two stocks.

About Harrow

(Get Free Report)

Harrow is a pharmaceutical company focused on developing, acquiring and commercializing treatments for eye conditions. Its portfolio includes prescription ophthalmic medicines used in areas such as dry eye disease, eye inflammation and pain management, as well as products used in eye surgery and clinical settings. The company markets branded products including VEVYE, a treatment for dry eye disease, and IHEEZO, an ophthalmic anesthetic gel. Through its ImprimisRx subsidiary, Harrow also provides compounded medications and related services for ophthalmology practices and patients.

About Liquidia

(Get Free Report)

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing treatments for pulmonary hypertension and other serious diseases. Its work includes inhaled therapies designed to deliver medicines to the lungs. The company’s marketed product, Yutrepia (treprostinil) inhalation powder, is approved in the United States for adults with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Liquidia also has a pipeline of investigational therapies, including other formulations of treprostinil.

Receive News & Ratings for Harrow Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow and related companies with MarketBeat.com's FREE daily email newsletter.